Prostatic acid phosphatase by IHC

Alphabetical Test listing

Prostatic acid phosphatase by IHC-12376 - Technical only, 12379 - Technical & interpretation

  
Prostatic acid phosphatase by IHC
  
12376 - Technical only, 12379 - Technical & interpretation
  
LAB12376
LAB12379
  
PSAP
  
  • All IHC stains will include a positive control tissue
  

PSAP is fairly specific for prostate tissue

  • Immunoreactivity for PSAP (and PSA) is generally more intense and homogeneous in benign prostate tissue than in prostatic carcinoma. Occasional cases of prostatic squamous metaplasia may show focal reactivity
  • Other normal/non-neoplastic tissues with reported PSAP reactivity:
    - periurethral glands*
    - anal glands (male only)*
    - urachal remnants*
    - renal tubules
    - neutrophils (cross reactivity with leukocyte acid phosphatase)
    - pancreatic islet cells
    - neuroendocrine cells in clonic crypts
    - seminal vesicle**
    - cystitis cystica and glandularis*
    - (rare reports of focal PSAP reactivity in hepatocytes, breast ducts, and gastric parietal cells)
  • Other neoplasms with reported PSAP reactivity:
    - pure adenocarcinoma of the bladder*
    - periurethral gland carcinomas*
    - gastrointestinal carcinoids (approx. 70% of rectal carcinoids; the frequency of PAP positivity decreases as one ascends the gastrointestinal tract)
    - pancreatic islet cell tumors
    - (rare reports of PSAP reactivity in renal cell carcinoma and breast carcinoma)
  • In general, any cloacal derived tissue may show reactivity with PSAP
  • Normal and neoplastic transitional epithelium is negative

Carcinoids found within the ovary, kidney, breast, liver, and head and neck have been PSAP negative

*both PSAP and PSA reactivity are reported
**reported for antibodies developed against seminal fluid.

Note:

PSAP monoclonal antibodies have shown a lower sensitivity compared to polyclonal antiserum (In two studies of poorly differentiated prostate carcinoma, monoclonal antibodies stained 59% and 60% of cases whereas polyclonal antibodies stained 83% and 86% of cases).

 

  
Tissue
  

Submit a formalin-fixed, paraffin embedded tissue block

  

Formalin-fixed, paraffin embedded (FFPE) tissue block

  

FFPE tissue section mounted on a charged, unstained slide

  

Ambient (preferred)

  
  • Unlabeled/mislabeled block
  • Insufficient tissue
  • Slides broken beyond repair
  
AHL - Immunohistochemistry
  
Mo - Fr
  
1 - 2 days
  

Immunohistochemical staining and microscopic examination

  

If requested, an interpretive report will be provided

  

Specifications

  • Monoclonal antibody directed against prostatic acid phosphatase

Staining pattern

  • Cytoplasmic based staining; prostatic acinar and ductal epithelium reactivity tends to concentrate in the apical portion. Reactivity is also present in prostatic secretions and on the surface of corpora amylacea

References

  1. Epstein JI. PSA and PSAP as immunohistochemical markers in prostate cancer. Urologic Clinics of North America 1993; 20(4):757-70.
  2. Ro JY, et al. Small cell carcinoma of the prostate: immunohistochemical and electron microscopic study of 18 cases. Cancer 1987; 59:977-82.
  3. Azumi. Prostatic acid phosphatase in carcinoid tumors. Am J Surg. Pathol 15(8):785-790, 1991.
  
88342 - 1st stain
88341 - each additional stain
  
08/08/2017
  
10/19/2018
  
10/02/2020